Trials / Completed
CompletedNCT03109717
Structural and Functional Connectivity of Brainstem Monoamine Pathways in Treatment Resistant Depression
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 11 (actual)
- Sponsor
- Kathryn O'Connor · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Study TRD subjects' resistance to at least 2 different antidepressants, we hypothesize that because of their significant depression and treatment resistant status they are most likely to exhibit BSMN pathway abnormalities.
Detailed description
Potential subjects will be identified during clinical visits. If a patient qualifies to participate in the study they will have to stop any antidepressants that they are taking to prepare for the use of MAOIs. After a two week washout period, subjects will have an fMRI and will be started on a MAOI. They will then be followed up for 8 weeks, which is routine and considered standard care.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Monoamine Oxidase Inhibitor (MAOI) | Monoamine Oxidase Inhibitor |
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2020-11-01
- Completion
- 2021-05-01
- First posted
- 2017-04-12
- Last updated
- 2021-06-18
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03109717. Inclusion in this directory is not an endorsement.